December 26, 2014 (Update) - On December 17, 2014, media reports stated that Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for NPS Pharmaceuticals Inc. On December 26, 2014, NASDAQ:NPSP shares closed at $36.60 per share.

June 9, 2014 (Shareholders Foundation) - An investigation on behalf of investors in NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shares was announced concerning whether a potential takeover of NPS Pharmaceuticals, Inc. would be unfair to investors in NASDAQ:NPSP shares.

The investigation by a law firm is at an early stage and concerns whether a takeover would be unfair to NASDAQ:NPSP investors.

On June 2, 2014, rumors surfaced that NPS Pharmaceuticals, Inc. might be taken over by Shire Plc. For $40 per NASDAQ:NPSP share.

However, given that at least one analyst has set the target price for NASDAQ:NPSP shares at $44 per share, the investigation a law firm concerns whether the NPS Pharmaceuticals Board of Directors will undertake an adequate sales process, adequately shop the company before entering into any transaction, maximize shareholder value by negotiating the best price, and act in the shareholders' best interests in connection with the proposed sale.

NPS Pharmaceuticals, Inc. reported that its annual Total Revenue increased from $101.64 million in 2011 to $155.59 million in 2013 and that its respective Net Loss declined from $36.27 million to $13.50 million. Shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) grew from $7.93 per share in March 2013 to as high as $39.06 per share in February 2014.